Published in J Virol Methods on March 27, 2006
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med (2011) 1.23
Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays. J Clin Microbiol (2010) 1.18
Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol (2011) 1.08
Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol (2008) 0.96
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer (2013) 0.94
Investigating a cluster of vulvar cancer in young women: a cross-sectional study of genital human papillomavirus prevalence. BMC Infect Dis (2012) 0.87
Improving oral human papillomavirus detection using toothbrush sampling in HIV-positive men who have sex with men. J Clin Microbiol (2014) 0.82
Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women. BMC Public Health (2014) 0.78
A case-control study of the role of human papillomavirus in oesophageal squamous cell carcinoma in australia. J Oncol (2014) 0.78
Effect of ThinPrep preparation on human papillomavirus detection and genotyping in rectal samples by PCR. J Clin Microbiol (2008) 0.77
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res (2012) 3.82
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis (2008) 3.05
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis (2005) 3.00
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis (2013) 2.40
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis (2006) 1.98
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol (2006) 1.78
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74
Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis (2012) 1.74
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine (2010) 1.57
Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by polymerase chain reaction among women living in remote areas. Sex Transm Dis (2002) 1.54
Human papillomavirus type 6 and 11 genetic variants found in 71 oral and anogenital epithelial samples from Australia. PLoS One (2013) 1.45
Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol (2011) 1.45
An audit of obstetricians' management of women potentially infected with blood-borne viruses. Med J Aust (2004) 1.42
Evaluation of opa-based real-time PCR for detection of Neisseria gonorrhoeae. Sex Transm Dis (2005) 1.39
The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin (2011) 1.35
Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Measurement of interleukin 8 in combination with C-reactive protein reduced unnecessary antibiotic therapy in newborn infants: a multicenter, randomized, controlled trial. Pediatrics (2004) 1.31
Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol (2005) 1.31
Oral human papillomavirus in men having sex with men: risk-factors and sampling. PLoS One (2012) 1.28
Transmission and selection of macrolide resistant Mycoplasma genitalium infections detected by rapid high resolution melt analysis. PLoS One (2012) 1.27
Development and evaluation of an ompA quantitative real-time PCR assay for Chlamydia trachomatis serovar determination. J Clin Microbiol (2010) 1.24
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med (2011) 1.23
Chlamydia trachomatis incidence and re-infection among young women--behavioural and microbiological characteristics. PLoS One (2012) 1.21
Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods (2007) 1.19
Characterization of Chlamydia trachomatis omp1 genotypes detected in eye swab samples from remote Australian communities. J Clin Microbiol (2004) 1.18
Human papillomavirus genotyping using archival vulval dysplastic or neoplastic biopsy tissues: comparison between the INNO-LiPA and linear array assays. J Clin Microbiol (2010) 1.18
A chlamydia prevalence survey of young women living in Melbourne, Victoria. Sex Health (2006) 1.18
HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol (2009) 1.18
Variability of the Chlamydia trachomatis omp1 gene detected in samples from men tested in male-only saunas in Melbourne, Australia. J Clin Microbiol (2004) 1.17
Bacterial vaginosis (BV) candidate bacteria: associations with BV and behavioural practices in sexually-experienced and inexperienced women. PLoS One (2012) 1.16
Evaluation of a modified reverse line blot assay for detection and typing of human papillomavirus. Am J Clin Pathol (2005) 1.15
Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia. Vaccine (2008) 1.15
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer (2011) 1.12
'The difference in determinants of Chlamydia trachomatis and Mycoplasma genitalium in a sample of young Australian women'. BMC Infect Dis (2011) 1.05
Anal and perianal squamous carcinomas and high-grade intraepithelial lesions exclusively associated with "low-risk" HPV genotypes 6 and 11. Int J Cancer (2013) 1.05
Prevalence of sexually transmitted infections among antenatal women in Vanuatu, 1999-2000. Sex Transm Dis (2003) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. Ann Clin Microbiol Antimicrob (2010) 1.01
A case-control study of mastitis: nasal carriage of Staphylococcus aureus. BMC Fam Pract (2006) 1.01
Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics (2013) 1.01
Chlamydia trachomatis genotypes among men who have sex with men in Australia. Sex Transm Dis (2011) 1.00
The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One (2013) 1.00
Exploring 'best practice' for nucleic acid detection of Neisseria gonorrhoeae. Sex Health (2008) 1.00
Attitudes to Chlamydia screening elicited using the social networking site Facebook for subject recruitment. Sex Health (2013) 1.00
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis (2013) 1.00
Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiol (2012) 0.99
Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS One (2013) 0.97
Knowledge of human papillomavirus and cervical cancer among young women recruited using a social networking site. Sex Transm Infect (2012) 0.96
Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol (2008) 0.96
Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health (2010) 0.96
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer (2011) 0.95
Prevalence of Gardnerella vaginalis and Atopobium vaginae in virginal women. Sex Transm Dis (2006) 0.95